Procurement Summary
Country: USA
Summary: Gmp Grade Human Interleukin2 Il2 from Acrobiosystems Inc
Deadline: 17 Jul 2026
Posting Date: 09 Jul 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 144816092
Document Ref. No.: 26-006951
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT
Title: GMP Grade Human Interleukin-2 (IL-2) from ACROBiosystems Inc.
Notice ID (POTS): 26-006951
Product Service Code (PSC): 6505 - Drugs and Biologicals
NAICS Code: 325414 - Biological Product (except Diagnostic) Manufacturing
Place of Performance: National Institutes of Health
Clinical Center
Bethesda, MD 20892
Description
This Notice of Intent (NOI) is issued for informational purposes only and does not constitute a Request for Quotations (RFQ). The Government does not intend to solicit competitive quotations for this requirement.
The National Institutes of Health (NIH), Clinical Center, Office of Acquisitions and Logistics Management (OALM), intends to award a sole source, firm-fixed-price purchase order to ACROBiosystems Inc., 1 Innovation Way, Suite 302, Newark, DE 19711, for the procurement of fifteen (15) vials of CytoPak GMP Human IL-2 Protein (Part Number: GMP-L02H14GB01), including shipping. The supplies support FDA-regulated cell and gene therapy manufacturing activities performed by the Center for Cellular Engineering (CCE).
Background
The Center for Cellular Engineering manufactures cell and gene therapies for NIH clinical trials. These FDA-regulated manufacturing processes require all components and materials to be validated to ensure product safety, quality, and consistency. The CytoPak GMP Human IL-2 Protein manufactured by ACROBiosystems has been validated for use in CCE's approved manufacturing processes. Substituting another manufacturer's product would require extensive process revalidation, resulting in significant cost and schedule impacts. During revalidation, patient treatment could be delayed, potentially causing disease progression that renders patients ineligible for clinical trials. Consequently, delaying this procurement would not be in the best interest of either the Government or the patients.
Sole Source Rationale
ACROBiosystems Inc. is the onl...
Notice ID: 26-006951
Department/Ind. Agency: health and human services, department of
Sub-tier: national institutes of health
Office: national institutes of health olao
Product Service Code: 6505 - drugs and biologicals
NAICS Code: 325414 - Biological Product (except Diagnostic) Manufacturing
Inactive Dates: jul 18, 2026
Inactive Policy: manual
Documents
Tender Notice